coa tirzepatide Original 2023788-19-2 manufacturer, Stock 367g, Assay 98.51% Buy the Tirzepatide | Research

As a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and weight management, tirzepatide acts on receptors throughout the central nervous system, influencing appetite regulation and potentially offering neuroprotective properties

For many of our patients, compounded is the better practical option but the right choice depends on your body, your health history, your budget, and your goals

With appropriate patient selection, realistic goal-setting, and comprehensive monitoring, tirzepatide represents an effective long-term tool for chronic weight management as part of a multifaceted treatment approach

However, the high retail prices in the US can be challenging for many patients